DOCSLIB.ORG
  • Sign Up
  • Log In
  • Upload
  • Sign Up
  • Log In
  • Upload
  • Home
  • »  Tags
  • »  Posaconazole

Posaconazole

  • ( 12 ) United States Patent

    ( 12 ) United States Patent

  • Addyi Generic Name: Flibanserin Manufacturer

    Addyi Generic Name: Flibanserin Manufacturer

  • M2021: Pharmacogenetic Testing

    M2021: Pharmacogenetic Testing

  • (Flibanserin) (Flibanserin) Tablets

    (Flibanserin) (Flibanserin) Tablets

  • Comparison of Clinical Pharmacology of Voriconazole and Posaconazole 367

    Comparison of Clinical Pharmacology of Voriconazole and Posaconazole 367

  • Aetna Formulary Exclusions Drug List

    Aetna Formulary Exclusions Drug List

  • Noxafil, INN-Posaconazole

    Noxafil, INN-Posaconazole

  • Cancer and Leukemia Group B

    Cancer and Leukemia Group B

  • Clinical Pearls: Significant Drug Interactions

    Clinical Pearls: Significant Drug Interactions

  • Prediction of Drug Interactions with Methadone, Buprenorphine and Oxycodone from in Vitro Inhibition of Metabolism

    Prediction of Drug Interactions with Methadone, Buprenorphine and Oxycodone from in Vitro Inhibition of Metabolism

  • Pharmacokinetics, Pharmacodynamics

    Pharmacokinetics, Pharmacodynamics

  • Attachment: Product Information: Ranolazine

    Attachment: Product Information: Ranolazine

  • Sacubitril/Valsartan

    Sacubitril/Valsartan

  • DRUG COVERAGE GUIDELINES Policy Number: PHARMACY 098.175 T0 Effective Date: June 1, 2018

    DRUG COVERAGE GUIDELINES Policy Number: PHARMACY 098.175 T0 Effective Date: June 1, 2018

  • Atypical Antipsychotics – Long-Acting Injectables

    Atypical Antipsychotics – Long-Acting Injectables

  • Memoria 2019, El Plan De Actuación 2019, Los Presupuestos De IDIVAL 2019 Y Ha Realizado Evaluación De Seguimiento De Cinco Grupos IDIVAL

    Memoria 2019, El Plan De Actuación 2019, Los Presupuestos De IDIVAL 2019 Y Ha Realizado Evaluación De Seguimiento De Cinco Grupos IDIVAL

  • List of Formulary Drug Removals

    List of Formulary Drug Removals

  • Antifungal Prophylaxis and Treatment in Paediatric Oncology Patients and Other Immunocompromised Children

    Antifungal Prophylaxis and Treatment in Paediatric Oncology Patients and Other Immunocompromised Children

Top View
  • Custom-Drug-List-Formulary.Pdf
  • Guidelines for Treatment of Invasive Aspergillosis and Mucormycosis in Patients on Pediatric Services
  • Drug-Drug Interaction Associated with Mold-Active Triazoles Among Hospitalized Patients
  • Ranexa 375 Mg Prolonged-Release Tablets Ranexa 500 Mg Prolonged-Release Tablets Ranexa 750 Mg Prolonged-Release Tablets Ranolazine
  • Your Prescription Benefit Updates
  • Major Drug Interactions with Cyclosporine and Tacrolimus
  • Posaconazole Versus Itraconazole As Prophylactic Antifungal Agents During Induction Chemotherapy for Acute Myeloid Leukemia: a Real-World Single Center Comparison
  • To Prescribe the New Drug Flibanserin
  • Supplemental Data for Drug Metabolism and Disposition
  • Noxafil Oral Suspension 40 Mg Per Ml (3) These Highlights Do Not Include All the Information Needed to Use NOXAFIL Safely and Effectively
  • Voriconazole More Likely Than Posaconazole Increases Plasma Exposure to Sublingual Buprenorphine Causing a Risk of a Clinically Important Interaction
  • ANTIRETROVIRAL CONTRAINDICATIONS and DRUG INTERACTIONS (Part of 5)
  • AHCCCS Pharmacy and Therapeutics Committee
  • The Effect of Posaconazole, Itraconazole and Voriconazole In
  • Fungal Infection Prevention After Hematopoietic Cell Transplantation
  • Vilazodone: a New Treatment for Major Depressive Disorder
  • Non-Invasive Management of Madura Foot with Oral Posaconazole and Ciprofloxacin
  • ODEFSEY (Emtricitabine, Rilpivirine, and Tenofovir


© 2024 Docslib.org    Feedback